Study on Safe Rivaroxaban Dosing for Elderly Chinese Patients with Pulmonary Embolism

What this Trial Is About

Researchers are exploring how to optimize the dosing of rivaroxaban, a blood thinner used to treat pulmonary embolism and venous thromboembolism, in elderly Chinese patients. This research addresses uncertainties in dosing for older adults, especially those with multiple medications and declining kidney and liver function, to better balance the risks of bleeding and clot recurrence. The study aims to find appropriate laboratory indicators to monitor rivaroxabans anticoagulant effects in this population. The study observes patients who have been diagnosed with acute symptomatic pulmonary embolism and are using direct oral anticoagulants like rivaroxaban. Participants take the medication as prescribed by their doctors, with doses adjusted based on clinical judgment. The study focuses on elderly patients during their anticoagulation maintenance phase. It monitors the drugs pharmacokinetic and pharmacodynamic properties to guide safe and effective dosing. During the study, participants will be regularly followed for about one year to track the recurrence of blood clots, fatal or non-fatal pulmonary embolism, and bleeding events categorized by established medical guidelines. Researchers will collect clinical data and lab tests to assess the drugs effects and safety. The study also observes patients overall health status and medication use to provide a comprehensive understanding of rivaroxaban dosing in high-risk elderly patients.

Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients